EUVIMEDEUVIMED entdecken
Crossref

Impact of the Immunonutritional Status on the Feasibility of Subsequent Treatment After the Discontinuation of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients With Metastatic Colorectal Cancer

Yuki Seki, Masatsune Shibutani, Hideki Tanda, Tomoya Tsukida, Hiroaki Kasashima, Shinichiro Kashiwagi, Kiyoshi Maeda

Anticancer Research · 2026

DOI: 10.21873/anticanres.18014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Yuki Seki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Nutrition Assessment, Geriatric Assessment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNutrition AssessmentGeriatric AssessmentFeasibility StudiesDrug CombinationsPyrrolidinesThymineTrifluridineBevacizumabRetrospective StudiesPrognosisSerum Albumin, HumanHumansMaleFemaleAgedTreatment Outcome

Stichwörter der Autor:innen

FTD/TPIbevacizumabcolorectal cancerimmune-nutritional statussubsequent treatment

Substanzen

trifluridine tipiracil drug combinationDrug CombinationsPyrrolidinesThymineTrifluridineBevacizumabSerum Albumin, Human

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; fbxbj429@ybb.ne.jp.
  • Department of Breast Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Zitieren

APA

Seki, Y., Shibutani, M., Tanda, H., Tsukida, T., Kasashima, H., Kashiwagi, S., & Maeda, K. (2026). Impact of the Immunonutritional Status on the Feasibility of Subsequent Treatment After the Discontinuation of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients With Metastatic Colorectal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.18014

Vancouver

Seki Y, Shibutani M, Tanda H, Tsukida T, Kasashima H, Kashiwagi S, et al. Impact of the Immunonutritional Status on the Feasibility of Subsequent Treatment After the Discontinuation of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients With Metastatic Colorectal Cancer. Anticancer Research. 2026. doi:10.21873/anticanres.18014

BibTeX
@article{Seki2026,
  author = {Seki, Yuki and Shibutani, Masatsune and Tanda, Hideki and Tsukida, Tomoya and Kasashima, Hiroaki and Kashiwagi, Shinichiro and Maeda, Kiyoshi},
  title = {Impact of the Immunonutritional Status on the Feasibility of Subsequent Treatment After the Discontinuation of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients With Metastatic Colorectal Cancer},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18014}
}
Kostenlos starten →